Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinji Takeuchi

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Chemosphere|January 1, 2014
Simple and rapid determination of PCDD/Fs in flue gases from various waste incinerators in China using DR-EcoScreen cellsZhiguang Zhou, Bin Zhao, Hiroyuki Kojima, et al.
Translational Lung Cancer Research|February 11, 2021
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, et al.
Hepatology International|November 14, 2024
Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practiceTakeshi Terashima, Tatsuya Yamashita, Kuniaki Arai, et al.
Frontiers in Oncology|April 16, 2025
Case Report: Medullary carcinoma of the pancreas with <i>MLH1</i> promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitorKoushiro Ohtsubo, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Clinical Colorectal Cancer|March 29, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF<sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramDaisuke Kotani, Atsuo Takashima, Takeshi Kato, et al.
Cancer Research|February 10, 2019
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation StatusKoji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.
International Journal of Clinical Oncology|March 1, 2021
Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern JapanShigeki Sato, Azusa Tanimoto, Naohiro Yanagimura, et al.
Cancer Science|November 30, 2019
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancerShinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2021
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancerHiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Chemosphere|January 1, 2014
Simple and rapid determination of PCDD/Fs in flue gases from various waste incinerators in China using DR-EcoScreen cellsZhiguang Zhou, Bin Zhao, Hiroyuki Kojima, et al.
Translational Lung Cancer Research|February 11, 2021
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, et al.
Hepatology International|November 14, 2024
Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practiceTakeshi Terashima, Tatsuya Yamashita, Kuniaki Arai, et al.
Frontiers in Oncology|April 16, 2025
Case Report: Medullary carcinoma of the pancreas with <i>MLH1</i> promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitorKoushiro Ohtsubo, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Clinical Colorectal Cancer|March 29, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF<sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramDaisuke Kotani, Atsuo Takashima, Takeshi Kato, et al.
Cancer Research|February 10, 2019
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation StatusKoji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.
International Journal of Clinical Oncology|March 1, 2021
Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern JapanShigeki Sato, Azusa Tanimoto, Naohiro Yanagimura, et al.
Cancer Science|November 30, 2019
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancerShinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2021
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancerHiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, et al.
Pageof 12